… post-bronchodilator FEV 1 /FVC ratio and FEV 1 %predicted. … patients, long-acting
bronchodilators, including long-acting muscarinic antagonists (LAMAs) and LAMA plus long-acting …

… with PIFR in patients with clinically stable COPD, especially in … spirometry (post-bronchodilator
force expiratory volume in 1 … as a predictive tool for optimal PIFR in clinically stable COPD …

… We conclude that a single measure of blood eosinophils may not be sufficient for predicting
… with severe COPD or if the COPD is not controlled by long-acting bronchodilators. Citation1,…

… of COPD was divided into four categories- (i) Long-acting … bronchodilator FEV1% predicted
and higher mMRC grading of … Participants in the present study had stable COPD, which …

… as long-acting β 2 -agonist (LABA)/long-acting muscarinic … cornerstone of treatment for patients
with stable COPD to improve … study can predict long-term drug efficacy characteristics, the …

… and patient traits that influence clinical results as a predictor … and long-acting agonist β2
(ICS-LABA) which is a therapy for … , including: stable COPD, diagnosed with COPD for at least 1 …

… patients in GOLD 2017 Group B, 19 (10.1%) in Group C and 123 (13.1%) in Group D were not
prescribed ICS or long-acting bronchodilators (… exacerbation may predict the occurrence of …

… spirometry (FEV 1 or FVC < 80% of predicted). A definition of … of a long-acting beta
agonist/long-acting muscarinic antagonist/… - or long-term bronchodilator, whereas patients in …

… with different PIF statuses directly assesses PIF as a predictive biomarker for treatment … a
post-BD change in PIF as a measure reflecting the change in IF in patients with stable COPD. …

… (LABA, Long-acting β 2 -Agonists; LAMA, Long-acting Muscarinic Antagonists; … in patients
with stable COPD, a higher level of blood eosinophils (albeit in the normal range) predicts a …